<SEC-DOCUMENT>0001213900-25-121465.txt : 20251215
<SEC-HEADER>0001213900-25-121465.hdr.sgml : 20251215
<ACCEPTANCE-DATETIME>20251215080014
ACCESSION NUMBER:		0001213900-25-121465
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251215
FILED AS OF DATE:		20251215
DATE AS OF CHANGE:		20251215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Radiopharm Theranostics Ltd
		CENTRAL INDEX KEY:			0001949257
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41621
		FILM NUMBER:		251570061

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		LEVEL 3, 62 LYGON STREET
		CITY:			CARLTON VIC
		PROVINCE COUNTRY:   	C3
		ZIP:			3053
		BUSINESS PHONE:		61 3 9824 5254

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		LEVEL 3, 62 LYGON STREET
		CITY:			CARLTON VIC
		PROVINCE COUNTRY:   	C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0269655-6k_radio.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the Month of December 2025</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: 001-41621</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>RADIOPHARM THERANOSTICS LIMITED</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name of Registrant)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive office)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Yes &#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>RADIOPHARM THERANOSTICS LIMITED</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXPLANATORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Radiopharm Theranostics Limited (the &ldquo;Company&rdquo;)
published an announcement (the &ldquo;Public Notice&rdquo;) to the Australian Securities Exchange on December 15, 2025 titled:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;RAD101 interim Phase 2b data - 92% achieve primary endpoint&rdquo;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-top: 0pt; vertical-align: bottom; width: 9%; border-bottom: black 1.5pt solid; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B> <BR>
<B>Number</B></FONT></TD>
    <TD STYLE="padding-top: 0pt; vertical-align: top; width: 1%; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><A HREF="ea026965501ex99-1_radio.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RAD101 interim Phase 2b data - 92% achieve primary endpoint</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RADIOPHARM THERANOSTICS LIMITED</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 62%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 15, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea026965501ex99-1_radio.htm
<DESCRIPTION>RAD101 INTERIM PHASE 2B DATA - 92% ACHIEVE PRIMARY ENDPOINT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left; width: 50%; vertical-align: top"><B>ASX ANNOUNCEMENT<BR>
  15 December 2025</B></TD>
  <TD STYLE="text-align: right; width: 50%">&nbsp;<IMG SRC="ex99-1_001.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="background-color: white"><B>Radiopharm
Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>92% of evaluable patients at interim analysis
treated with RAD 101 achieved concordance&sup1; with MRI imaging (the primary endpoint) with significant and selective tumor uptake in
suspected or recurrent brain metastases</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Company to host webinar on Tuesday, December
16 at 10:00 am AEDT (Australia) / Monday, December 15 at 6:00 pm EST (U.S.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sydney, Australia&ndash; 15 December 2025 &ndash; Radiopharm Theranostics
(ASX:RAD, &ldquo;Radiopharm&rdquo; or the &ldquo;Company&rdquo;), a clinical-stage biopharmaceutical company focused on developing innovative
oncology radiopharmaceuticals for areas of high unmet medical need, today announced interim data from the first twelve patients in its
U.S. Phase 2b clinical imaging trial of RAD 101 in brain metastases. RAD 101 is Radiopharm&rsquo;s novel, small-molecule imaging agent
targeting fatty acid synthase (FASN) and radiolabelled with Fluorine-18 for the diagnosis of suspected recurrent brain metastases from
solid tumors of different origins, also known as the Pivalate technology.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The interim analysis showed that 92% (11/12) of the patients treated
with RAD 101 achieved concordance with MRI (the primary endpoint) as assessed by PET imaging of brain metastases. The results showed significant
and selective tumor uptake in the brain metastases. Images confirm metabolic activity in brain metastases compared to equivocal MRI findings.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;These compelling interim data significantly strengthen confidence
in the success of our Phase II trial of RAD 101 and provide a strong foundation for initiating a pivotal study by the end of 2026,&rdquo;
said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. &ldquo;Integrating RAD 101 PET (Pivalate) with standard
MRI has the potential to transform patient management and enable better treatment decisions for the more than 300,000 patients in the
U.S. diagnosed with brain metastases each year. Independent commercial assessments estimate RAD 101&rsquo;s U.S. market opportunity at
more than $500 million annually, positioning it to become one of the top three imaging agents in the market.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company recently achieved 50% patient enrollment in the Phase 2b
trial evaluating RAD 101 imaging in brain metastases and RAD 101 has received&nbsp;U.S. Food and Drug Administration (FDA) Fast Track
Designation to distinguish between recurrent disease and treatment effect of brain metastases originating from solid tumors of different
origin, including leptomeningeal disease.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the U.S. alone, there are more than 300,000 patients diagnosed annually
with cerebral metastases. The incidence of Intracranial Metastatic Disease (IMD) continues to increase, in part, due to improvements in
systemic therapy resulting in a more durable control of the Primary tumor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify">Concordance definition: &ldquo;Agreement or correlation between
MRI and Pivalate images&rdquo;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Radiopharm Theranostics
Limited<BR>
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia<BR>
ABN: 57 647 877 889</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left; width: 50%; vertical-align: top"><B>ASX ANNOUNCEMENT<BR>
  15 December 2025</B></TD>
  <TD STYLE="text-align: right; width: 50%">&nbsp;<IMG SRC="ex99-1_001.jpg" ALT=""></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contrast-enhanced Magnetic Resonance Imaging (CE-MRI) is the preferred
method for imaging IMD, but has limitations, particularly in follow-up surveillance scans to optimise patient care.&sup2;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>WEBINAR DETAILS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AUSTRALIA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Date: </B>Tuesday 16 December 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Time: </B>10:00am AEDT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>USA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Date: </B>Monday 15 December 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Time: </B>6.00pm EST</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Presenters:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Riccardo Canevari &ndash; CEO &amp; Managing Director</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Dr Dimitris Voliotis &ndash; Chief Medical Officer</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Dr Harshad Kulkarni &ndash; BAMF Health, Grand Rapids, MI</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Register for the webinar at the link below: </B>https://us02web.zoom.us/webinar/register/WN_aV5mGG4aT0embNN8JgzDOw</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Please submit any questions to: </B>matt@nwrcommunications.com.au</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon registering attendees will receive an email containing information
about joining the webinar. A recording will be available at the above link soon after the conclusion of the live session, with the replay
to also be made available via Radiopharm&rsquo;s website and social media channels.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About the Phase 2 Clinical Trial of RAD101 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The U.S. multi-center, open-label, single
arm Phase 2b clinical trial is evaluating the diagnostic performance of 18F-RAD101 in 30 individuals with confirmed recurrent brain
metastases from solid tumors of different origins. The primary objective of the study is concordance between 18F-RAD101 positive
lesions and those seen in conventional imaging (MRI with gadolinium) in participants with suspected recurrent brain metastases.
Secondary endpoints are accuracy, sensitivity and specificity of RAD101 in identifying tumor recurrence versus radiation necrosis in
previously stereotactic radiosurgery (SRS)-treated brain metastases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>2</SUP></TD><TD STYLE="text-align: justify">A hybrid [18F]fluoropivalate PET-multiparametric MRI to detect
and characterise brain tumour metastases based on a permissive environment for monocarboxylate transport | European Journal of Nuclear
Medicine and Molecular Imaging</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Radiopharm Theranostics
Limited<BR>
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia<BR>
ABN: 57 647 877 889</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left; width: 50%; vertical-align: top"><B>ASX ANNOUNCEMENT<BR>
  15 December 2025</B></TD>
  <TD STYLE="text-align: right; width: 50%">&nbsp;<IMG SRC="ex99-1_001.jpg" ALT=""></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About RAD101</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RAD101 is the Company&rsquo;s novel imaging small molecule that targets
fatty acid synthase (FASN), a multi-enzyme protein that catalyses fatty acid synthesis and is overexpressed in many solid tumors, including
cerebral metastasis. Targeting FASN activity may allow for the more accurate detection of cancer cells, representing a clinically relevant
method for the imaging of brain metastases. Positive data from the Imperial College of London&rsquo;s Phase 2a imaging trial of 18F-RAD101
in patients with brain metastases (both SRS pre-treated and treatment na&iuml;ve patients) showed significant tumor uptake that was independent
from the tumor of origin. The study further indicated that PET-MRI may potentially represent a non-invasive prediction of overall-survival,
warranting larger studies.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Radiopharm Theranostics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Radiopharm Theranostics is a clinical stage radiotherapeutics
company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas
of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly
differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program
includes one Phase 2 and four Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn
more at radiopharmtheranostics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Authorised on behalf of the Radiopharm Theranostics board of directors
by Chairman Paul Hopper.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For more information:</B><BR>
Riccardo Canevari<BR>
CEO &amp; Managing Director<BR>
P: +1 862 309 0293<BR>
E: rc@radiopharmtheranostics.com</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Anne Marie Fields</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Precision AQ (Formerly Stern IR)</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">E: annemarie.fields@precisionaq.com</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Paul Hopper<BR>
Executive Chairman<BR>
P: +61 406 671 515<BR>
E: paulhopper@lifescienceportfolio.com</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Media</U><BR>
Matt Wright<BR>
NWR Communications<BR>
P: +61 451 896 420<BR>
E: matt@nwrcommunications.com.au</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Radiopharm Theranostics
Limited<BR>
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia<BR>
ABN: 57 647 877 889</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !$ ,@# 2(  A$! Q$!_\0
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M\15JX;%4U5PE;#3H^RFN:E5H5Z52CB83B])*I&K4I5$]7":CHFF?W)_L_?\
M!+SX+_M9_ 3X??'OX&?M)W=WX>^(&@V^I);ZIX'M;N?P]K:((->\*ZVFG^+T
M>UUKPWK$=WI6I6Q0 2V_GP--:S6\TL7C#_@B'\=M,A>7P7\4/AGXK*(6$&K'
MQ#X5NI6 ^[$BZ3KUH&;^'S;^-!SND &3_-9_P3:_X*E?''_@G3XXN9/"ZCQ[
M\&/%=_;W'Q"^#VM:A/;:5J4B(EN?$7A>^5+D^%_&%O:HD*:I!:7-IJ=M#!8Z
MWI]_!;V+V/\ =#^Q]_P5@_8I_;0TK34^'GQ7TCPA\0;J&'[=\(_B;>:?X/\
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M9K+'-<77A/2CJOBJ$1@K)J&E:=I[,)M1MU?]7$1(U5$541%5$1%"JB* %55
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; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
